The key driving factor for the development of the global Alzheimer’s drug market is the increasing prevalence of the disease in the developed countries in the West. Numerous neurodegenerative disease have become increasingly prevalent in the countries such as the U.S. in the past few years, leading to a steady support from the government to develop drug for treatment. This has thus resulted in a highly favorable market conditions for the drug manufacturers of the Alzheimer’s disease and consequently driving the growth of the market in the region.

Source: Click here